• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Editorial: Novel Therapeutic Potential for Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP), Vasoactive Intestinal Peptide (VIP) and Related Peptides in Cognition Deficits.

作者信息

Ciranna Lucia, Reglodi Dora, Chow Billy K, Vaudry David

机构信息

Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy.

Department of Anatomy, PTE-MTA PACAP Research Team, University of Pecs Medical School, Pecs, Hungary.

出版信息

Front Cell Neurosci. 2021 Sep 13;15:748970. doi: 10.3389/fncel.2021.748970. eCollection 2021.

DOI:10.3389/fncel.2021.748970
PMID:34588958
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8473805/
Abstract
摘要

相似文献

1
Editorial: Novel Therapeutic Potential for Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP), Vasoactive Intestinal Peptide (VIP) and Related Peptides in Cognition Deficits.社论：垂体腺苷酸环化酶激活多肽（PACAP）、血管活性肠肽（VIP）及相关肽在认知缺陷中的新型治疗潜力
Front Cell Neurosci. 2021 Sep 13;15:748970. doi: 10.3389/fncel.2021.748970. eCollection 2021.
2
A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.克隆的蛙血管活性肠肽/垂体腺苷酸环化酶激活肽受体具有哺乳动物中VPAC1和VPAC2受体的药理学及组织分布特征。
Endocrinology. 1999 Mar;140(3):1285-93. doi: 10.1210/endo.140.3.6576.
3
Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary.垂体腺苷酸环化酶激活多肽、血管活性肠肽及其受体在小鼠卵巢中的表达定位与功能活性
Reproduction. 2007 Aug;134(2):281-92. doi: 10.1530/REP-07-0051.
4
Properties of the pituitary adenylate cyclase-activating polypeptide I and II receptors, vasoactive intestinal peptide1, and chimeric amino-terminal pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide1 receptors: evidence for multiple receptor states.垂体腺苷酸环化酶激活多肽I和II受体、血管活性肠肽1以及嵌合氨基末端垂体腺苷酸环化酶激活多肽/血管活性肠肽1受体的特性：多种受体状态的证据
Mol Pharmacol. 1996 Dec;50(6):1596-604.
5
Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) stimulate interleukin-6 production through the third subtype of PACAP/VIP receptor in rat bone marrow-derived stromal cells.垂体腺苷酸环化酶激活多肽（PACAP）和血管活性肠肽（VIP）通过大鼠骨髓来源的基质细胞中PACAP/VIP受体的第三种亚型刺激白细胞介素-6的产生。
Endocrinology. 1997 Jun;138(6):2515-20. doi: 10.1210/endo.138.6.5169.
6
Characterization and expression of different pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptors in rat ovarian follicles.大鼠卵巢卵泡中不同垂体腺苷酸环化酶激活多肽/血管活性肠肽受体的特性与表达
J Endocrinol. 2006 Oct;191(1):287-99. doi: 10.1677/joe.1.06470.
7
Pituitary adenylate cyclase-activating polypeptide receptors mediating insulin secretion in rodent pancreatic islets are coupled to adenylate cyclase but not to PLC.介导啮齿动物胰岛胰岛素分泌的垂体腺苷酸环化酶激活多肽受体与腺苷酸环化酶偶联，但不与磷脂酶C偶联。
Endocrinology. 2002 Apr;143(4):1253-9. doi: 10.1210/endo.143.4.8739.
8
Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin.人肿瘤及其起源组织中的血管活性肠肽/垂体腺苷酸环化酶激活肽受体亚型
Cancer Res. 2000 Jun 1;60(11):3105-12.
9
Pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal peptide inhibit dendritic growth in cultured sympathetic neurons.垂体腺苷酸环化酶激活多肽和血管活性肠肽抑制培养的交感神经元的树突生长。
J Neurosci. 2002 Aug 1;22(15):6560-9. doi: 10.1523/JNEUROSCI.22-15-06560.2002.
10
VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.VPAC2受体介导垂体腺苷酸环化酶激活肽/血管活性肠肽对原代大鼠脂肪细胞的脂解作用。
Endocrinology. 2005 Feb;146(2):744-50. doi: 10.1210/en.2004-0504. Epub 2004 Oct 28.

引用本文的文献

1
Antimicrobial Neuropeptides and Their Receptors: Immunoregulator and Therapeutic Targets for Immune Disorders.抗菌神经肽及其受体：免疫失调的免疫调节剂和治疗靶点
Molecules. 2025 Jan 27;30(3):568. doi: 10.3390/molecules30030568.

本文引用的文献

1
Activation of Serotonin 5-HT Receptors Modulates Hippocampal Synaptic Plasticity by Stimulation of Adenylate Cyclases and Rescues Learning and Behavior in a Mouse Model of Fragile X Syndrome.血清素5-羟色胺受体的激活通过刺激腺苷酸环化酶调节海马突触可塑性，并挽救脆性X综合征小鼠模型中的学习和行为。
Front Mol Neurosci. 2018 Oct 2;11:353. doi: 10.3389/fnmol.2018.00353. eCollection 2018.
2
Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Enhances Hippocampal Synaptic Plasticity and Improves Memory Performance in Huntington's Disease.垂体腺苷酸环化酶激活肽（PACAP）增强亨廷顿病中海马突触可塑性和改善记忆功能。
Mol Neurobiol. 2018 Nov;55(11):8263-8277. doi: 10.1007/s12035-018-0972-5. Epub 2018 Mar 10.
3
PACAP protects against salsolinol-induced toxicity in dopaminergic SH-SY5Y cells: implication for Parkinson's disease.PACAP 可防止多巴胺能 SH-SY5Y 细胞中的蝇蕈醇诱导的毒性：对帕金森病的影响。
J Mol Neurosci. 2013 Jul;50(3):600-7. doi: 10.1007/s12031-013-0015-7. Epub 2013 Apr 28.
4
Optogenetic stimulation of a hippocampal engram activates fear memory recall.光遗传学刺激海马体的记忆痕迹会激活恐惧记忆的回忆。
Nature. 2012 Mar 22;484(7394):381-5. doi: 10.1038/nature11028.
5
Neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) slows down Alzheimer's disease-like pathology in amyloid precursor protein-transgenic mice.神经肽垂体腺苷酸环化酶激活肽（PACAP）可减缓淀粉样前体蛋白转基因小鼠的类似阿尔茨海默病的病理变化。
FASEB J. 2011 Sep;25(9):3208-18. doi: 10.1096/fj.10-180133. Epub 2011 May 18.
6
The cyclic AMP phenotype of fragile X and autism.脆性X综合征和自闭症的环磷酸腺苷表型
Neurosci Biobehav Rev. 2008 Oct;32(8):1533-43. doi: 10.1016/j.neubiorev.2008.06.005. Epub 2008 Jun 17.
7
Differential regulation of activity-dependent neuroprotective protein in rat astrocytes by VIP and PACAP.血管活性肠肽和垂体腺苷酸环化酶激活肽对大鼠星形胶质细胞中活性依赖神经保护蛋白的差异调节
Regul Pept. 2004 Dec 15;123(1-3):33-41. doi: 10.1016/j.regpep.2004.05.021.